Jefferies on CytomX Therapeutics (CTMX): 'we see good entry point at current value' amid Vareseta-M derisking

March 24, 2026 10:19 AM

Jefferies analyst Roger Song reiterated a Buy rating and $16.00 price target on CytomX Therapeutics (NASDAQ: CTMX)The analyst commented, "We ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found